capecitabine has been researched along with Body Weight in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Dietrich, D; Figer, A; Gerber, D; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, BC; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K | 1 |
| Bell, D; Black, G; Ferrucci, LM; Heimburger, DC; McCorkle, R; Saif, MW; Thornton, J | 1 |
| Cao, F; Han, N; He, K; Jin, K; Lan, H; Li, G; Teng, L; Xie, B; Xu, Z | 1 |
| Endo, M; Fukase, Y; Ishikawa, T; Ishitsuka, H; Sawada, N; Shinbori, N; Tanaka, Y | 1 |
2 trial(s) available for capecitabine and Body Weight
| Article | Year |
|---|---|
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Deoxycytidine; Drug Administration Schedule; Europe; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Parenteral; Karnofsky Performance Status; Male; Middle Aged; Pain; Pain Measurement; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Time Factors; Treatment Failure | 2008 |
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study.
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Linear Models; Male; Middle Aged; Nutritional Status; Pancreatic Neoplasms; Pilot Projects; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2011 |
2 other study(ies) available for capecitabine and Body Weight
| Article | Year |
|---|---|
Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Carcinoma; Colonic Neoplasms; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Neovascularization, Pathologic; Proliferating Cell Nuclear Antigen; Radiography; Recombinant Fusion Proteins; Thymidine Phosphorylase; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Humans; Kinetics; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Thymidine Phosphorylase; Time Factors; Up-Regulation | 1999 |